在细胞癌中,纳纳米辛K抑制了细胞增殖和上皮细胞-介质细胞过渡
Aya Hiraoka1, Yuto Hirata1, Yuki Kan1
1Department of Public Health, Kobe University Graduate School of Health Sciences.
Biological & pharmaceutical bulletin
|December 1, 2024
概括
纳纳米辛K是一种天然化合物,通过阻断表皮细胞-介质细胞过渡 (EMT) 来有效抑制细胞癌 (RCC) 的生长和迁移. 这种化合物显示出作为高级RCC的潜在治疗剂的希望.
科学领域:
- 自然产品 化学 化学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 表皮-介质细胞过渡 (EMT) 是癌细胞迁移和转移的一个关键机制.
- 细胞癌 (RCC) 是癌症相关死亡的一个重要原因.
- 确定针对EMT的新型治疗剂对于改善RCC治疗结果至关重要.
研究的目的:
- 研究纳纳米辛K在细胞癌 (RCC) 中的EMT抑制和抗瘤作用.
- 在RCC的临床前模型中评估Nanaomycin K的疗效.
主要方法:
- 在体外研究中,使用RCC细胞系 (ACHN,Caki-1,Renca) 用纳纳米K治疗.
- 细胞增殖,细胞亡和迁移的评估 (伤口愈合试验).
- 在体内研究,涉及瘤携带的小鼠,接受了纳纳米K.治疗.
主要成果:
- 纳纳米辛K显著抑制了RCC细胞生长,迁移和诱导的亡,特别是在转化生长因子 (TGF) -β的存在下.
- 基因表达分析显示,纳纳米辛K对EMT标记物 (增加E-cadherin,减少N-cadherin,Vimentin,Slug) 和亡标记物 (促进Caspase-3,8,9) 的调节.
- 纳纳米辛K的内注射显著抑制了体内瘤的生长,没有观察到任何不良影响.
结论:
- 纳纳米辛K在RCC中表现出强大的抗增殖,抗迁移和亲产的作用.
- 纳纳米辛K有效抑制TGF-β诱导的EMT在先进的RCC.
- 纳纳米辛K是RCC治疗中一个有前途的治疗候选药物.
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Replicative Cell Senescence
3.6K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


